Organizational Governance

Andy Molnar, CEO of the Digital Therapeutics Alliance, discusses the definition of a digital therapeutic, companies in the DTx space, why the organization held its recent summit in D.C. and the status of the Prescription Digital Therapeutics Act.  

Dave Bailey, VP, Consulting Services at Clearwater Security, recommends developing cybersecurity strategy around a framework like NIST 2.0 and working with leadership to get the necessary resources to address vulnerabilities.  

McGill University Health Centre's Dr. Alan Forster discusses the Quadruple Aim and using data to understand opportunities for development and improvement.  

Andy Molnar, CEO of the Digital Therapeutics Alliance, and Scott Stuewe, president and CEO of DirectTrust, discuss their partnership to show digital therapeutics' value and accreditation in healthcare for payors considering DTx coverage.  

Kyruus Health president Paul Merrild discusses how the company aims to improve care access via its partnerships with health systems and payers and by pairing patients and providers using personalized information and provider availability.  

Cole Wiser, executive creative director at the Virtual Wild, and Srini Iyer, chief technology officer for Leidos' health and civil sector, discuss using holograms for immersive training and patient interactions.  

Oscar Alleyne, managing director of the public health division at MITRE, relays how federally funded research and development centers help public and private companies solve complex problems, including preparing for the next pandemic.  

The ONC's new rules could include advancements around public health IT certification requirements, electronic prior authorization, patient engagement tools and refinement to info blocking rules, says Sean Sullivan, a partner at Alston & Bird.  

David Wolf, MedeAnalytics AVP, and Lynn Carroll, HSBlox COO, highlight value-based care models' crucial components, including contract modeling and performance measurement, and discuss change management for switching to these models.  

Ziv Ofek, cofounder and CEO of MDClone, discusses how GenAI tools may soon make it easier for clinicians to analyze synthetic data themselves if guardrails are in place to ensure that the AI's conclusions are correct.